Cryo-Cell International, Inc. engages in cord blood and cord tissue cryopreservation services in the United States. The company offers cellular processing and ...
Cryo-Cell International, Inc. (NYSE: CCEL) is a healthcare company specializing in the collection, processing, and cryogenic storage of umbilical cord blood and cord tissue stem cells for family use. As the pioneer in the private cord blood banking industry, Cryo-Cell has built a strong reputation for innovation and quality, serving ...Cryo-Cell International, Inc. (NYSE: CCEL) is a healthcare company specializing in the collection, processing, and cryogenic storage of umbilical cord blood and cord tissue stem cells for family use. As the pioneer in the private cord blood banking industry, Cryo-Cell has built a strong reputation for innovation and quality, serving over 500,000 parents across 87 countries since its founding in 1989 by Dan Richard. The company is headquartered in Oldsmar, Florida, and operates with a dedicated team of approximately 72 employees.
The company's primary products include cord blood and cord tissue storage services, with a focus on preserving stem cells for future medical treatments. Additionally, Cryo-Cell manufactures PrepaCyte CB processing systems, which are used to efficiently process cord blood stem cells. Beyond family banking, the company provides cold storage services to third-party pharmaceutical companies and medical institutions, leveraging its expertise in cryopreservation.
Financially, Cryo-Cell reported a market capitalization of $28.3 million as of 2023, with a stock price of $3.51. The company generates revenue primarily from storage fees and processing services, with a gross profit margin of 77.3%. Despite a negative net profit margin of -7.9% in the trailing twelve months, the company maintains a strong operating cash flow, indicating resilience in its core operations. The company pays a dividend of $0.65 per share, reflecting a commitment to returning value to shareholders.
Leadership is shared by Co-CEOs David Portnoy and Mark Portnoy, who have been guiding the company since 2011. Their strategic direction focuses on expanding market reach and enhancing service offerings. Cryo-Cell is recognized as an industry leader, with a history of pioneering innovations such as the separation and storage of stem cells from cord blood. The company's commitment to excellence has earned it the trust of healthcare professionals and families worldwide.
YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength.
QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes.
RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three).
$31.6M
-1.3%
+1.2%
Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day.
$-2.4M
-704.2%
+1077.3%
Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials.
+76.6%
+2.0%
-3.0%
Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on).
+15.3%
+41.0%
+54.6%
Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales.
-7.7%
-712.2%
+1063.2%
Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock.
$5.2M
+118.0%
+210.1%
FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine.
+16.6%
+120.9%
+206.4%
Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe.
-62.1%
+36.5%
-287.6%
Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking.
0.59x
+2.2%
+13.8%
Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground.
